Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy

Table 2

Anti-Parkinson agents used for the treatment of the two patient groups.

Patient number	PD group	Treatment
1	LRRK2-PD	Carbidopa/levodopa 300 mg
2		Carbidopa/levodopa 300 mg
3		Carbidopa/levodopa 500 mg, pramipexole 0.7 mg ×3
4		Carbidopa/levodopa 400 mg, pergolide 1 mg ×3
5		Carbidopa/levodopa 500 mg, pramipexole 0.7 mg ×3
6		Carbidopa/levodopa 400 mg
7		Carbidopa/levodopa 200 mg, STN DBS
8		Carbidopa/levodopa 550 mg, pramipexole 0.7 mg ×3
9		Carbidopa/levodopa 300 mg
10		Carbidopa/levodopa 400 mg, ropinirole 18 mg, selegiline 10 mg
11	Sporadic PD	Carbidopa/levodopa 1000 mg
12		Carbidopa/levodopa 1000 mg, pramipexole 0.7 mg ×3
13		Carbidopa/levodopa 300 mg, ropinirole 20 mg
14		Carbidopa/levodopa 300 mg
15		Cabergoline 3 mg
16		Carbidopa/levodopa 400 mg, pramipexole 0.18 mg ×3
17		Carbidopa/levodopa 600 mg, pramipexole 0.7 mg ×3
18		Carbidopa/levodopa 400 mg
19		Carbidopa/levodopa 800 mg, pramipexole 0.7 mg ×4
20		Carbidopa/levodopa 400 mg, pramipexole 0.36 mg ×3, selegiline 10 mg
21		Carbidopa/levodopa 150 mg, cabergoline 3 mg
22		Carbidopa/levodopa 300 mg, STN DBS
23		Carbidopa/levodopa 300 mg
24		Carbidopa/levodopa 300 mg, rotigotine 12 mg
25		Carbidopa/levodopa 400 mg, selegiline 10 mg
26		Carbidopa/levodopa 200 mg, STN DBS
27		Pramipexole 0.36 mg ×3, selegiline 10 mg

Patient number 19 also took an antidepressant, escitalopram 10 mg. Selegiline is a monoamine oxidase-B inhibitor. STN DBS = deep brain stimulation of the subthalamic nucleus.